Organogenesis Holdings financials
$1.39+0.36%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.8M | $37.2M | $225.6M | $150.9M | $101.0M | $86.7M | $126.7M | $115.2M | $130.2M | $110.0M | $99.7M | $108.5M |
| Gross profit | $43.8M | $37.2M | $225.6M | $150.9M | $101.0M | $86.7M | $126.7M | $115.2M | $130.2M | $81.3M | $71.9M | $82.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 73.9% | 72.1% | 76.2% |
| Operating income | -$51.0M | -$68.9M | $63.3M | $20.7M | -$12.6M | -$26.7M | $10.2M | $6.2M | -$13.9M | -$3.9M | -$1.3M | $8.1M |
| Net income | -$99.3M | -$53.2M | $35.1M | $14.5M | -$12.2M | -$18.8M | $5.9M | $12.3M | -$17.0M | -$2.1M | -$568.0K | $3.2M |
| Net margin | −227.0% | −142.8% | 15.6% | 9.6% | −12.1% | −21.7% | 4.6% | 10.7% | −13.1% | −1.9% | −0.6% | 2.9% |
| Diluted EPS | $-0.77 | $-0.44 | $0.26 | $0.11 | $-0.10 | $-0.17 | $0.05 | $0.09 | $-0.13 | $-0.02 | $0.00 | $0.02 |
| EBITDA | -$46.9M | -$59.0M | $70.1M | $26.5M | -$8.0M | -$15.9M | $14.7M | $10.6M | $13.1M | $121.0K | -$1.3M | $11.8M |
| Operating cash flow | -$31.7M | $21.1M | $39.4M | $3.1M | -$32.9M | -$19.9M | $10.9M | $8.7M | $4.7M | -$10.2M | $10.6M | $16.7M |
| Free cash flow | -$32.8M | $18.0M | $34.8M | $844.0K | -$36.5M | -$23.6M | $7.6M | $6.1M | $2.9M | -$12.4M | $7.3M | $10.8M |
| Diluted shares | 128.7M | 127.8M | 137.0M | 130.8M | 126.9M | 126.3M | 128.3M | 133.9M | 132.6M | 131.9M | 133.4M | 133.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $46.1M | $91.4M | $93.7M | $63.7M | $73.1M | $110.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $11.7M | $39.9M | $22.2M | $8.7M | $7.7M | $1.6M |
| Total assets | $406.4M | $520.0M | $598.7M | $509.8M | $461.1M | $467.4M |
| Total liabilities | $118.3M | $138.6M | $164.8M | $123.8M | $99.9M | $99.3M |
| Shareholders' equity | $148.3M | $244.6M | $300.1M | $255.1M | $233.2M | $242.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology